Siliq, Kyntheum (brodalumab) is an antibody pharmaceutical. Brodalumab was first approved as Siliq on 2017-02-15. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-17 receptor A.
|Drug Class||Monoclonal antibodies: fully human, immunomodulating|